Receive Our Newsletter

Search Results for 'von Willebrand Disease;'

Filter by: All | Page | News Article | Resource

BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR

FOR IMMEDIATE RELEASE Media Contacts Doreen Eaton, (805) 372-3417 Marie Kennedy, (805) 372-3543 Investor Contacts Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085 BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR Three Baxter Scientists Granted […]

BioRx Offers Scholarships to Bleeding Disorders Community

Link to article September 1, 2010 (Cincinnati, Ohio) BioRx and Hemophilia of North Carolina announce the availability of four 2011 BioRx Educational Scholarships in the amount of $2,000 each to individuals with bleeding disorders. The scholarships will be awarded for the 2011-2012 school year, and the deadline for submitting applications is May 1, 2011. BioRx […]

Grifols Alphanate vCJD Labeling Press Release

FOR IMMEDIATE RELEASE FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD Alphanate® is the first plasma-derived blood clotting factor to include labeling statements on manufacturing processes that provide a reasonable assurance of removal for low levels of a variant Creutzfeldt-Jakob disease (vCJD) model agent. Barcelona, Spain (March […]

Assisting and Advocating for the Bleeding Disorders Community